T1D Innovations, LLC

A severe lack of resources for translational research, which is the work necessary to bring scientific breakthroughs into human clinical testing, is preventing many of the innovations flowing out of academic labs from impacting the lives of patients. In the case of type 1 diabetes (“T1D”), this deficit is particularly pronounced: over $275 million is spent annually on basic research and yet until now there have been no venture funds or venture-creating entities dedicated to the disease. T1D Innovations, LLC (“T1D Innovations”) was formed by the Juvenile Diabetes Research Foundation (JDRF), the world’s largest non-profit supporter of T1D research, and PureTech Ventures, LLC (“PureTech”), a venture creation company, to address this need. This initiative will create and fund high-impact companies that will develop innovative type 1 diabetes-related products with the potential to have a substantial clinical impact on T1D patients. Joslin Diabetes Center and T1D Exchange join PureTech and Anchor Partner JDRF as Special Partners. These foundations will bring their valuable scientific, clinical, and patient engagement capabilities to the collaboration.

T1D Innovations is a vehicle for mission-focused not-for-profits and other strategic and financial investors to work with PureTech, an institutional entrepreneur, to develop solutions for T1D.

Financial description

T1D innovations’ investors invest directly in the mission-focused LLC and receive, in return, an equity stake in the company. This investment is directed toward the company’s venture creation activities, with a focus on funding critical development and commercialization activities for transformational technologies in type 1 diabetes. Investors participate in governance of the LLC, particularly for the purpose of ensuring mission compliance, and will have the opportunity to participate even more deeply in a business or scientific capacity.
As promising individual technologies are identified, they are spun off as separate wholly-owned subsidiaries of the company (“NewCos”) and are structured as C-corporations.